Industry Briefs: Feb. 20, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Apricus Bioscience’s wholly owned subsidiary NexMed (USA) has signed with Sandoz, a division of Novartis, an exclusive collaboration for Germany to market Apricus Bio’s Vitaros (alprostadil) drug for treating erectile dysfunction. Read More
The Biomedical Advanced Research and Development Authority has awarded a contract worth up to $67 million for the development of a Tetraphase Antibiotic. Read More
Catalent Pharma Solutions has completed the acquisition of the clinical trials supplies business of Aptuit. Read More
FDA issued a Warning Letter to West-Ward Pharmaceticals for significant violations of cGMP regulations for finished pharmaceuticals. Read More
Mylan plans to change the name of its specialty subsidiary from Dey Pharma to Mylan Specialty. Read More
OncoPep has entered an exclusive license agreement with Dana-Farber for therapeutic multipeptide-vaccine technology for hematologic cancers. Read More
Quintiles plans to expand its commercial services in the Middle East and North Africa region through an agreement with Dayarn Pharma. Read More
Wyeth Pharmaceuticals (now part of Pfizer) seeks $960 million in damages from Sun Pharmaceutical for alleged patent infringement. Read More
People News
Amgen has named Michael Severino senior vice-president of global development and corporate chief medical officer. Read More
Astellas has appointed Charlotte M. E. Kremer as senior vice-president of its global medical affairs organization. Read More
Hospira has appointed Zena G. Kaufman as senior vice-president of quality. Read More
OSO BioPharmaceuticals has named Milton Boyer president of manufacturing. Read More
Patheon has appointed Stuart Grant as executive vice-president and chief financial officer. Read More
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
